

IDS 2/06/02

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 018733-1089	SERIAL NO. Unassigned
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANT Gary L. GRIFFITHS et al.	
		FILING DATE 02/06/2002	GROUP ART UNIT Unassigned

U.S. PATENT DOCUMENTS


EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
J	A1	3,927,193	12/16/1975	Hansen et al			
J	A2	4,331,647	05/25/1982	Goldenberg			
J	A3	4,348,376	09/07/1982	Goldenberg			
J	A4	4,361,544	11/30/1982	Goldenberg			
J	A5	4,468,457	08/28/1984	Goldenberg et al.			
J	A6	4,444,744	04/24/1984	Goldenberg			
J	A7	4,460,459	07/17/1984	Shaw et al.			
J	A8	4,460,561	07/17/1984	Goldenberg			
J	A9	4,036,945	07/19/1977	Haber			
J	A10	4,735,210	04/05/1988	Goldenberg			
J	A11	5,851,527	12/22/1998	Hansen			

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
J	A12	91/09134	06/27/1991	WIPO				
J	A13	0 501 215 A2	02/10/1992	EPO				
J	A14	96/20011	07/04/1996	WIPO				
J	A15	97/41898	11/13/1997	WIPO				
J	A16	99/42593	08/26/1999	WIPO				
J	A17	99/66951	12/29/1999	WIPO				


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

J	A18	TRAIL ET AL., "Cure of Xenografted Human Carcinomas by BR96-Doxorubicin Immunoconjugates", Science, 1993, pp. 212-215, Vol. 261.
J	A19	TRAIL ET AL., "Effect of Linker Variation on the Stability, Potency, and Efficacy of Carcinomareactive BR64-Doxorubicin Immunoconjugates", Cancer Res., 1997, pp. 100-105, Vol. 57.
J	A20	ARCAMONE, "Properties of Antitumor Anthracyclines and New Developments in Their Application: Cain Memorial Award Lecture", Cancer Res., 1985, pg. 5995, Vol. 45.

EXAMINER 	DATE CONSIDERED 6/04
---	-------------------------

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

PTO
10/06/02
02/06/02

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 018733-1089		SERIAL NO. Unassigned	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				APPLICANT Gary L. GRIFFITHS et al.			
				FILING DATE 02/06/2002		GROUP ART UNIT Unassigned	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
1	A21	POTTER ET AL., "Isolation and Partial Characterization of a cDNA Encoding a Rabbit Liver Carboxylesterase That Activates the Prodrug Irinotecan (CPT-11)", Cancer Res., 1998, pp. 2646-2651, Vol. 58.					
1	A22	POTTER ET AL., "Cellular Localization Domains of a Rabbit and Human Carboxylesterase: Influence on Irinotecan (CPT-11) Metabolism by the Rabbit Enzyme", Cancer Res., 1998, pp. 3627-3632, Vol. 58.					
	A23	WANG ET AL., "Specific Activation of Glucuronide Prodrugs by Antibody-Targeted Enzyme Conjugates for Cancer Therapy", Cancer Res., 1992, pp. 4484-4491, Vol. 52.					
	A24	BAKINA ET AL., "Intensely Cytotoxic Anthracycline Prodrugs: Glucuronides", J. Med Chem., 1997, pp. 4013-4018, Vol. 40.					
	A25	SCHMIDT ET AL., "Glucuronide Prodrugs of Hydroxy Compounds For Antibody Directed Enzyme Prodrug Therapy (Adept) A Phenol Nitrogen Mustard Carbamate", Bioorg. Med Chem. Lett., 1997, pp. 1071-1076, Vol. 7.					
	A26	GUPTA ET AL., "Pharmacokinetic Modulation of Irinotecan and Metabolites by Cyclosporin A", Cancer Res., 1996, pp. 1309-1314, Vol. 56.					
	A27	GUPTA ET AL., "Modulation of Glucuronidation of SN-38, The Active Metabolite of Irinotecan, by Valproic Acid and Phenobarbital", Cancer Chemother. Pharmacol., 1997, pp. 440-444, Vol. 39.					
	A28	MELTON ET AL., "Antibody-Directed Enzyme Prodrug Therapy (ADEPT) Review Article", Drugs of the Future 1996, pp. 167-181, Vol. 21, No. 2, Barcelona, Spain.					
	A29	HAY ET AL., "Antibody-Directed Enzyme Prodrug Therapy (ADEPT)", Drugs of the Future, 1996, pp. 917-931, Vol. 21, No. 9.					
1	A30	TAKAYAMA ET AL., "Synthesis of a New Class of Camptothecin Derivatives, The Long-Chain Fatty Acid Esters of 10-Hydroxycamptothecin, as a Potent Prodrug Candidate, and Their In Vitro Metabolic Conversion by Carboxylesterases", Bioorganic & Medicinal Chemistry Letters, 1998, pp. 415-418, Vol. 8, No. 5, Oxford, Great Britain.					
EXAMINER 				DATE CONSIDERED 6/04			
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.							

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 018733-1089		SERIAL NO. Unassigned	
INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>				APPLICANT Gary L. GRIFFITHS et al.			
				FILING DATE 02/06/2002		GROUP ART UNIT Unassigned	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
1	A31	DANKS ET AL., "Comparison of Activation of CPT-11 by Rabbit and Human Carboxylesterases for Use in Enzyme/Prodrug Therapy", Clinical Cancer Research, 1999, pp. 917-924, Vol. 5, No. 4.					
2	A32	LEU ET AL., "Design and Synthesis of Water-Soluble Glucuronide Derivatives of Camptothecin for Cancer Prodrug Monotherapy and Antibody-Directed Enzyme Prodrug Therapy (ADEPT)", Journal of Medicinal Chemistry, 1999, pp. 3623-3628, Vol. 42, No. 18.					
EXAMINER				DATE CONSIDERED			
				6/04			
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.							